18 results on '"Karadkhele, Geeta"'
Search Results
2. Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
- Author
-
Johnson, Aileen C., Karadkhele, Geeta M., Shenvi, Neeta, Easley, Kirk A., Larsen, Christian P., and Badell, I. Raul
- Published
- 2023
- Full Text
- View/download PDF
3. Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial
- Author
-
Badell, Idelberto R., Parsons, Ronald F., Karadkhele, Geeta, Cristea, Octav, Mead, Sue, Thomas, Shine, Robertson, Jennifer M., Kim, Grace S., Hanfelt, John J., Pastan, Stephen O., and Larsen, Christian P.
- Published
- 2021
- Full Text
- View/download PDF
4. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept
- Author
-
Karadkhele, Geeta, Hogan, Julien, Magua, Wairimu, Zhang, Weiwen, Badell, Idelberto Raul, Mehta, Aneesh, Lyon, Marshall, Pastan, Stephen, Pearson, Thomas C., and Larsen, Christian P.
- Published
- 2021
- Full Text
- View/download PDF
5. 311.4: Every 2-Month Belatacept Maintenance Therapy in Kidney Transplant Recipients: 3-Year Follow-up of a Randomized, Non-inferiority Trial
- Author
-
Johnson, Aileen, Karadkhele, Geeta, Shenvi, Neeta, Easley, Kirk, Larsen, Christian P, and Badell, Idelberto R
- Published
- 2022
- Full Text
- View/download PDF
6. Longitudinal Evaluation of Cytopenias in the Renal Transplant Population
- Author
-
Johnson, Aileen C., Karadkhele, Geeta, Magua, Wairimu, Vasanth, Payas, and Larsen, Christian P.
- Published
- 2022
- Full Text
- View/download PDF
7. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation
- Author
-
Badell, Idelberto Raul, Karadkhele, Geeta M., Vasanth, Payaswini, Farris, Alton Brad, III, Robertson, Jennifer M., and Larsen, Christian P.
- Published
- 2019
- Full Text
- View/download PDF
8. The Burden and Impact of Early Post-transplant Multidrug-Resistant Organism Detection Among Renal Transplant Recipients, 2005–2021.
- Author
-
Babiker, Ahmed, Karadkhele, Geeta, Bombin, Andrei, Watkins, Rockford, Robichaux, Chad, Smith, Gillian, Beechar, Vivek B, Steed, Danielle B, Jacobs, Jesse T, Read, Timothy D, Satola, Sarah, Larsen, Christian P, Kraft, Colleen S, Pouch, Stephanie M, and Woodworth, Michael H
- Abstract
Background Reducing the burden of multidrug-resistant organism (MDRO) colonization and infection among renal transplant recipients (RTRs) may improve patient outcomes. We aimed to assess whether the detection of an MDRO or a comparable antibiotic-susceptible organism (CSO) during the early post-transplant (EPT) period was associated with graft loss and mortality among RTRs. Methods We conducted a retrospective cohort study of RTRs transplanted between 2005 and 2021. EPT positivity was defined as a positive bacterial culture within 30 days of transplant. The incidence and prevalence of EPT MDRO detection were calculated. The primary outcome was a composite of 1-year allograft loss or mortality following transplant. Multivariable Cox hazard regression, competing risk, propensity score–weighted sensitivity, and subgroup analyses were performed. Results Among 3507 RTRs, the prevalence of EPT MDRO detection was 1.3% (95% CI, 0.91%–1.69%) with an incidence rate per 1000 EPT-days at risk of 0.42 (95% CI, 0.31–0.57). Among RTRs who met survival analysis inclusion criteria (n = 3432), 91% (3138/3432) had no positive EPT cultures and were designated as negative controls, 8% (263/3432) had a CSO detected, and 1% (31/3432) had an MDRO detected in the EPT period. EPT MDRO detection was associated with the composite outcome (adjusted hazard ratio [aHR], 3.29; 95% CI, 1.21–8.92) and death-censored allograft loss (cause-specific aHR, 7.15; 95% CI, 0.92–55.5; subdistribution aHR, 7.15; 95% CI, 0.95–53.7). A similar trend was seen in the subgroup and sensitivity analyses. Conclusions MDRO detection during the EPT period was associated with allograft loss, suggesting the need for increased strategies to optimize prevention of MDRO colonization and infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Risk factors and outcomes of bloodstream infection from a urinary source in kidney transplant recipients.
- Author
-
Eichenberger, Emily M., Donzo, Maja Wichhart, Anderson, Rebecca, Karadkhele, Geeta, Pouch, Stephanie M., and Larsen, Christian P.
- Subjects
KIDNEY transplantation ,URETHRA stricture ,ESCHERICHIA coli ,BACTERIURIA ,NEUROMUSCULAR diseases ,KIDNEY failure - Abstract
Background: Bacteriuria is common among kidney transplant recipients (KTR). Risk factors and outcomes associated with bloodstream infection due to a urinary source (BSIU) in KTR are poorly understood. Methods: This single center case‐control study from 2010 to 2022 compared KTR with BSIU to those with bacteria without bloodstream infection (BU). Multivariable logistic regression identified BSIU risk factors, and Cox models assessed its impact on graft failure. Results: Among 3435 patients, who underwent kidney transplantation at Emory Hospital, 757 (22%) developed bacteriuria, among whom 142 (18.8%) were BSIU. Male sex, presence of Escherichia coli, Klebsiella pneumoniae, or Pseudomonas species in urine culture, urethral stricture, neuromuscular bladder disorder, and history of diabetes‐induced renal failure were independently associated with increased odds of BSIU (Male sex: aOR 2.29, 95% CI 1.52, 3.47, E. coli: aOR 5.14, 95% CI 3.02, 9.13; K. pneumoniae aOR 3.19, 95% CI 1.65, 6.27, Pseudomonas spp aOR 3.06, 95% CI 1.25, 7.18; urethral stricture: 4.10, 95% CI 1.63, 10.3, neuromuscular bladder disorder aOR 1.98, 95% CI 1.09, 3.53, diabetes: aOR 1.64, 95% CI 1.08, 2.49). BSIU was associated with increased hazard of graft failure (HR 1.52, 95% CI 1.05, 2.20). Conclusion: Close monitoring is warranted for male KTR with bacteriuria, those with urine cultures positive for Pseudomonas spp, K. pneumoniae, or E. coli, as well as KTR with a history of diabetes‐induced renal failure, urethral stricture, or neuromuscular bladder disorder due to their risk for developing BSIU. Future research should explore strategies to mitigate BSIU risk in these high‐risk KTR and reduce the associated risk of long‐term graft failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
- Author
-
Beechar, Vivek B., Pouch, Stephanie M., Phadke, Varun K., Karadkhele, Geeta, Larsen, Christian P., and Woodworth, Michael H.
- Subjects
KIDNEY transplantation ,NUCLEIC acids ,CYTOMEGALOVIRUSES ,VIRAL load ,MORTALITY ,BK virus - Abstract
Background: Cytomegalovirus (CMV) infection has broad implications for morbidity and mortality in renal transplant recipients (RTR). Routine surveillance for CMV replication with PCR‐based quantitative nucleic acid testing (qNAT) assays is standard practice in most transplant centers, but the impact of assay sensitivity on antiviral decision‐making and virologic outcomes has not been studied. We investigated the effects of an ultrasensitive CMV qNAT assay on multiple clinical outcomes, including time to detection and duration of CMV DNAemia. Methods: We conducted a single‐center cohort study contrasting RTRs monitored with a qNAT with a higher lower limit of quantification (LLOQ >300 IU/mL) with those monitored with a more sensitive qNAT (LLOQ >35 IU/mL). Patients were stratified by donor (D)/recipient (R) CMV serostatus (D+/R−: high risk; any R+: moderate risk). CMV viral load monitoring was performed monthly post transplantation, with the primary outcomes being time to CMV DNAemia and its duration. Results: Total 1382 patients were analyzed from 2014 to 2016 and 2019 to 2021. Moderate‐risk RTRs monitored with the more sensitive assay experienced a greater hazard for the development of a first episode of CMV DNAemia (aHR: 1.95, 95% confidence interval [CI]: 1.55–2.46) and an average of 24 (95% CI: 16.40–31.98) additional days of DNAemia. There was no difference in CMV end‐organ disease or 1‐year all‐cause mortality between moderate‐risk RTRs. Conclusions: The more sensitive assay was associated with earlier detection and extended durations of CMV DNAemia in moderate‐risk RTRs, without altering clinical outcomes. These findings inform optimal use of these assays and antiviral stewardship in RTRs. Key Summary: The use of ultrasensitive CMV qNAT assays in moderate‐risk CMV renal transplant recipients is associated with earlier detection and longer durations of CMV DNAemia without impacting CMV end‐organ disease or 1‐year mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Post-transplant lymphoproliferative disorder risk and outcomes in renal transplant patients treated with belatacept immunosuppression.
- Author
-
Koff, Jean L., Karadkhele, Geeta M., Switchenko, Jeffrey M., Rupji, Manali, Little, Kendra, and Larsen, Christian P.
- Published
- 2024
- Full Text
- View/download PDF
12. Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement.
- Author
-
Woodworth, Michael H., Conrad, Roth E., Haldopoulos, Marina, Pouch, Stephanie M., Babiker, Ahmed, Mehta, Aneesh K., Sitchenko, Kaitlin L., Wang, Charlotte H., Strudwick, Amanda, Ingersoll, Jessica M., Philippe, Cécile, Lohsen, Sarah, Kocaman, Kumru, Lindner, Blake G., Hatt, Janet K., Jones, Rheinallt M., Miller, Candace, Neish, Andrew S., Friedman-Moraco, Rachel, and Karadkhele, Geeta
- Subjects
FECAL microbiota transplantation ,DRUG resistance in microorganisms ,MULTIDRUG resistance in bacteria ,SHORT-chain fatty acids ,MULTIDRUG resistance - Abstract
Multidrug-resistant organism (MDRO) colonization is a fundamental challenge in antimicrobial resistance. Limited studies have shown that fecal microbiota transplantation (FMT) can reduce MDRO colonization, but its mechanisms are poorly understood. We conducted a randomized, controlled trial of FMT for MDRO decolonization in renal transplant recipients called PREMIX (NCT02922816). Eleven participants were enrolled and randomized 1:1 to FMT or an observation period followed by delayed FMT if stool cultures were MDRO positive at day 36. Participants who were MDRO positive after one FMT were treated with a second FMT. At last visit, eight of nine patients who completed all treatments were MDRO culture negative. FMT-treated participants had longer time to recurrent MDRO infection versus PREMIX-eligible controls who were not treated with FMT. Key taxa (Akkermansia muciniphila, Alistipes putredinis, Phocaeicola dorei, Phascolarctobacterium faecium, Alistipes species, Mesosutterella massiliensis, Barnesiella intestinihominis, and Faecalibacterium prausnitzii) from the single feces donor used in the study that engrafted in recipients and metabolites such as short-chain fatty acids and bile acids in FMT-responding participants uncovered leads for rational microbiome therapeutic and diagnostic development. Metagenomic analyses revealed a previously unobserved mechanism of MDRO eradication by conspecific strain competition in an FMT-treated subset. Susceptible Enterobacterales strains that replaced baseline extended-spectrum β-lactamase–producing strains were not detectable in donor microbiota manufactured as FMT doses but in one case were detectable in the recipient before FMT. These data suggest that FMT may provide a path to exploit strain competition to reduce MDRO colonization. Editor's summary: Those who must use antibiotic prophylaxis to prevent opportunistic infections are at high risk for intestinal colonization and infection by multi-drug resistant organisms (MDROs). Here, Woodworth and colleagues conducted a randomized controlled trial to compare the safety, efficacy, and strain dynamics of MDRO eradication after bowel preparation plus fecal microbiota transfer (FMT) versus bowel preparation alone in 11 renal transplantation recipients. FMT resulted in faster MDRO decolonization and protected study participants from recurrent infection. In some participants, extended spectrum β-lactamase (ESBL)–producing strains were replaced by non-ESBL strains, suggesting that strain competition rather than eradication may occur after FMT. These findings support the efficacy of FMT and provide valuable insights into the mechanisms by which FMT may lead to MDRO decolonization. —Melissa Norton [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high‐risk cytomegalovirus serostatus kidney transplant recipients.
- Author
-
Magua, Wairimu, Johnson, Aileen C., Karadkhele, Geeta M., Badell, Idelberto R., Vasanth, Payaswini, Mehta, Aneesh K., Easley, Kirk A., Newell, Kenneth A., Rickert, Joseph B., and Larsen, Christian P.
- Subjects
VIRAL load ,BELATACEPT ,KIDNEY transplantation ,TACROLIMUS ,CYTOMEGALOVIRUSES - Abstract
Background: Belatacept improves long‐term graft survival, but control of some primary viral infections may be impaired. We evaluated the impact of belatacept and tacrolimus on cytomegalovirus (CMV) viral control, remission and relapse in CMV high‐risk and moderate‐risk recipients. Methods: Using a multistate Markov model, we evaluated viral load state transitions of 173 kidney transplant recipients with at least one episode of viremia within 1 year after transplant: state 1, undetectable/low viral load; state 2, moderate viremia; and state 3, severe viremia. Results: Among high‐risk recipients, belatacept‐treated recipients exhibited a significantly higher probability of entering moderate viremia (.36; 95% CI =.31,.41) than tacrolimus‐treated recipients (.20; 95% CI =.13,.29). The expected number of days in viremic states differed. High‐risk belatacept‐treated recipients persisted in moderate viremia for significantly longer (128 days, 95% CI = 110, 146) than did tacrolimus‐treated recipients (70.0 days, 95% CI = 45.2, 100) and showed a trend of shorter duration in low/undetectable viral load state (172 days, 95% CI = 148, 195) than did tacrolimus‐treated recipients (239 days, 95% CI = 195, 277). Moderate‐risk recipients showed better viral load control and with no differences by immunosuppression. Conclusion: High‐risk belatacept‐treated recipients showed defects in sustaining viral control relative to tacrolimus‐treated recipients. Avoidance of initial use belatacept in high‐risk recipients or development of modified management protocols should be considered. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States.
- Author
-
Karadkhele, Geeta, Duneton, Charlotte, Garro, Rouba, Badell, Idelberto Raul, Pearson, Thomas C., Larsen, Christian P., and Hogan, Julien
- Subjects
- *
BELATACEPT , *KIDNEY transplantation , *GRAFT rejection , *IMMUNOSUPPRESSIVE agents - Abstract
The adoption of de novo belatacept in kidney transplant (kTx) recipients was hampered by an increased risk of acute cellular rejection (ACR) with variation in adopted belatacept based immunosuppressive therapies across centers. We used data from the Scientific Registry of Transplant Recipients (SRTR) to evaluate the temporal trends in belatacept use and describe the associated induction and maintenance regimens in US adult kTx recipients transplanted between June 2011 and December 2018. The number of patients receiving de novo‐belatacept based immunosuppressive therapy increased from.74% in 2011 to 3.11% in 2016. In 2016, 66/207 centers used de novo belatacept‐based regimen with 3.03% using it in over 50% of their patients. The use of T‐cell depleting agents increased with time. Since 2012, the rate of calcineurin inhibitor (CNI) use in combination with belatacept remained stable around 50% and ∼30% remained under belatacept/CNI combination at 1‐year post‐transplantation. The adoption of belatacept as de novo immunosuppressive regimen has been slow and its use remains low in the United States. Various regimens have been used to modulate the risk of ACR. Further studies evaluating the long‐term outcomes of these regimens and assessing their safety especially with regard to the risk of infection are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation.
- Author
-
Zhang, Weiwen, Morris, Anna B., Peek, Erica V., Karadkhele, Geeta, Robertson, Jennifer M., Kissick, Haydn T., and Larsen, Christian P.
- Subjects
T cell differentiation ,CYTOMEGALOVIRUS diseases ,CYTOTOXIC T cells ,T cells ,PSYCHONEUROIMMUNOLOGY ,VIRUS diseases - Abstract
Cytomegalovirus (CMV) is one of the most commonly recognized opportunistic pathogens and remains the most influential known parameter in shaping an individual's immune system. As such, T cells induced by CMV infection could have a long-term impact on subsequent immune responses. Accumulating evidence indicates that memory T cells developed during past bacterial and viral infection can cross-react with unrelated pathogens, including transplant antigens, and can alter responses to de novo infections, vaccines, cancers, or rejection. Therefore, careful examination of T cell responses elicited by CMV is warranted to understand their potentially beneficial or harmful roles in future major immune events. Our detailed exploration of the distribution, phenotype, TCR repertoire and transcriptome of CD4+ T cells within CMV seropositive healthy individuals using high-dimensional flow cytometry and single cell multi-omics sequencing reveals that CMV seropositivity has highly significant age-independent effects, leading to a reduction in CD4+ naïve T cells and an expansion of CD4+ effector memory T cells and CD45RA+ effector memory T cells. These induced CD4+ effector memory T cells undergo a specific differentiation trajectory resulting in a subpopulation of CD57+CD27-CD28-CD244+ CD4+ T cells with cytotoxic function and TCR oligoclonality for optimal controlled coexistence with cytomegalovirus. Through gene set enrichment analysis, we found that this subpopulation is similar to virus-specific CD8+ T cells and T cells that mediate acute rejection in patients using tacrolimus and belatacept, a selective costimulation blocker. Together, these data suggest that memory CD4+ T cells induced by cytomegalovirus are formed via a distinct differentiation program to acquire cytotoxic function and can be potentially detrimental to transplant patients adopting costimulation blockade immunosuppressive regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Belatacept-based immunosuppression does not confer increased risk of BK polyomavirus-DNAemia relative to tacrolimus-based immunosuppression.
- Author
-
Eichenberger EM, Magua W, Rickert JB, Karadkhele G, Fallahzadeh MK, Vasanth P, and Larsen C
- Abstract
Background: The effect of belatacept on BK polyomavirus (BKPyV) control remains largely unknown., Methods: This is a propensity matched retrospective cohort study in adult kidney transplant recipients (KTR) transplanted between 2016-2020 who received a belatacept- versus tacrolimus-based immunosuppression regimen. A continuous time multi-state Markov model was used to evaluate BKPyV replication dynamics (BKPyV-dyn). Three BKPyV-dyn states were defined: BKPyV-dyn1 (viral load <3 log
10 ), BKPyV-dyn2 (viral load ≥ 3 log10 and ≤4 log10 ), and BKPyV-dyn3 (viral load >4 log10 )., Results: Two hundred eighty KTR on belatacept- and 280 KTR on tacrolimus-based regimens were compared. The probability of transitioning between BKPyV-dyn states and time spent in each state in both groups was comparable. Total duration in BKPyV-dyn-1 was 632.1 days (95% CI 612.1, 648.5) for belatacept versus 615.2 days (95% CI 592.5, 635.8) for tacrolimus, BKPyV-dyn-2 was 49.2 days (95% CI 41.3, 58.4) for belatacept versus 55.6 days (95% CI 46.5, 66.8) for tacrolimus, and BKPyV-dyn-3 was 48.7 days (95% CI 37.1, 363.1) for belatacept versus 59.2 days (95% CI 45.8, 73.5) for tacrolimus. BKPyV associated nephropathy (PyVAN) occurred in 3.9% in belatacept- and 3.9% tacrolimus-treated KRT (P > .9)., Conclusions: Compared with tacrolimus-based immunosuppression, belatacept based immunosuppression was not associated with increased risk of BKPyV-DNAemia or nephropathy., (© 2024 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
17. Belatacept Conversion in Kidney After Liver Transplantation.
- Author
-
Cristea O, Karadkhele G, Kitchens WH, Vasanth P, Larsen CP, and Badell IR
- Abstract
Background: Costimulatory blockade with belatacept has demonstrated long-term benefits in renal transplantation, but de novo use in liver transplant recipients has resulted in increased rejection, graft loss, and death. However, belatacept conversion as a calcineurin inhibitor (CNI) avoidance strategy has not been studied and may be of benefit in liver transplantation where CNI-induced renal dysfunction and toxicity are barriers to improved outcomes., Methods: Using clinical data extracted from our institutional medical record, we report on 8 patients who underwent kidney after liver transplantation and were treated with belatacept-based immunosuppression and transient CNI therapy., Results: All patients tolerated belatacept therapy without any patient deaths or graft losses. No episodes of rejection, de novo donor-specific antibody formation, or major systemic infections were observed, and all patients demonstrated preserved liver and excellent renal allograft function. Patients received belatacept for a median duration of 13.2 mo, and at a median follow-up of 15.9 mo post-kidney transplant, 6 of 8 patients continued on belatacept with 3 completely off and 3 poised to transition off CNI., Conclusions: These findings are the first evidence that in liver transplant recipients requiring subsequent kidney transplantation, belatacept-based therapy can potentially facilitate CNI-free maintenance immunosuppression. This supports the possibility of belatacept conversion in stand-alone liver transplant recipients as a viable method of CNI avoidance., Competing Interests: The authors declare no funding or conflicts of interest., (Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
18. Sex and Glomerular Filtration Rate Trajectories in Children.
- Author
-
Bonnéric S, Karadkhele G, Couchoud C, Patzer RE, Greenbaum LA, and Hogan J
- Subjects
- Adolescent, Child, Child, Preschool, Disease Progression, Female, Humans, Infant, Kidney surgery, Kidney Transplantation, Longitudinal Studies, Male, Progression-Free Survival, Prospective Studies, Renal Dialysis, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic mortality, Renal Insufficiency, Chronic therapy, Risk Assessment, Risk Factors, Sex Factors, Time Factors, Glomerular Filtration Rate, Kidney physiopathology, Renal Insufficiency, Chronic physiopathology
- Abstract
Background and Objectives: Differences in CKD progression by sex have been hypothesized to explain disparities in access to kidney transplantation in children. This study aims to identify distinct trajectories of eGFR decline and to investigate the association of sex with eGFR decline., Design, Setting, Participants, & Measurements: We used data from the CKD in Children study. Latent class mixed models were used to identify eGFR trajectories and patient characteristics were compared between trajectories. Progression was studied to two outcomes: ESKD (dialysis or transplantation) and a combined outcome of ESKD or 50% eGFR decline from baseline, using multivariable parametric failure time models., Results: Among 888 patients, 613 with nonglomerular and 275 with glomerular diseases, we observed four and two distinct GFR trajectories, respectively. Among patients with nonglomerular diseases, there was a higher proportion of males in the group with a low baseline GFR. This group had an increased risk of ESKD or 50% GFR decline, despite a similar absolute decline in GFR. Eight patients with nonglomerular diseases, mostly males with obstructive uropathies, had a more rapid absolute GFR decline. However, the association between male sex and rapid absolute GFR decline was NS after adjustment for age, baseline GFR, and proteinuria. Among patients with glomerular diseases, a subgroup including mostly females with systemic immunologic diseases or crescentic GN had a rapid absolute GFR decline., Conclusions: This study identifies different trajectories of CKD progression in children and found a faster progression of CKD in females in patients with glomerular diseases, but no significant sex difference in patients with nonglomerular diseases. The differences in progression seem likely explained by sex differences in the underlying primary kidney disease and in baseline GFR rather than by a direct effect of sex on progression., (Copyright © 2020 by the American Society of Nephrology.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.